Some clinical studies have shown that PD-L1, tumor mutational burden (TMB), microsatellite instability (MSI), defective mismatch repair (dMMR) and other immune features are considered as potential biomarkers for predicting ICIs [3–6]. The gene discussed is CD274; the disease is neoplasm.